Research and Reports in Immunology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - Research and Reports in Immunology (2022) Volume 5, Issue 2

Structure and function of HIV enveloped glycoproteins as targets for entry mediators, vaccine immunogens, and inhibitors.

Joseph Ilunga*

Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria

*Corresponding Author:
Joseph Ilunga
Department of Biotechnology
University of Natural Resources and Life Sciences
Vienna, Austria

Received: 25-Mar-2022, Manuscript No. AARRI-22-108; Editor assigned: 28-Mar-2022, Pre QC No. AARRI-22-108 (PQ); Reviewed: 11-Apr-2022, QC No. AARRI-22-108; Revised: 18-Apr-2022; AARRI-22-108 (R); Published: 25-Apr-2022, DOI: 10.35841/aarri-5.2.108

Citation: Ilunga J. Structure and function of HIV enveloped glycoproteins as targets for entry mediators, vaccine immunogens, and inhibitors. Res Rep Immunol. 2022;5(2):108

Visit for more related articles at Research and Reports in Immunology


Viral membrane-related glycoproteins Envelope virus life cycle. They attach virions to cells by binding to host cell receptors some of the subsequent steps of membrane fusion and viral entry, directly Morphogenesis of budding progeny virions and, in some cases, Receptor-destroying enzyme activity for virion release and prevention Superinfection. HIV is no exception. It’s Envelope Glycoprotein (Env) At least two functions important to the HIV replication cycle-binding using either the receptor (CD4) or the co-receptor (CCR5 or CXCR4) with two non-covalent subunits, gp120, and a virus Protoplasmic cell membrane mediated by the other subunit gp41. That is also, important antigens and immunogens that are neutralized by all known Antibodies are indicated. This chapter focuses on the advancement of knowledge about the structure and function of Env related to its interaction with CD4. Co-receptors and neutralizing antibodies focused on the conservation of Env Structural elements that can be used in the design of vaccine immunogens and inhibitors. Many excellent reviews have been published Can provide details about various aspects of the environment and act as a source of additional citations.

Like many other viral envelope glycoproteins, HIVenv Two subunits involved in binding, surface glycoprotein (SU) Receptor molecules and trans membrane glycoproteins (TM), It mediates the fusion of the viral membrane and the plasma membrane. Originally synthesized as a non-fusion polyprotein precursor, gp160 Env is cleaved into SU (gp120) and TM by the host cell protease (furin). (Gp41) A subunit that remains a non-covalent bond. See this complex is the same as gp120-gp41, but also uses the abbreviation Env to represent a functional fusion HIV envelope glycoprotein. Like other viral envelope glycoproteins, Env is an oligomer. Current the accepted view is that it is gp120 gp41 [1]. It is highly glycosylated and has a relatively high molecular weight the weight of the monomer, which accounts for about half of the mass, is about 160 kDa Carbohydrat [2].

HIV has developed various strategies to avoid host immune surveillance, primarily through environmental changes. Our recent progress. We promise to provide an understanding of its structure in atomic level details It provides new tools for developing effective vaccines and inhibitors [3]. Regardless of Significant progress, contribution to vaccine development, there is still a wealth of information about the therapeutic Env structure. Relatively small but current development promises a revolution How therapeutics and vaccines will be designed in the future. Remain It is not yet known if this promise will be kept. The envelope glycoproteins (Envs) of HIV-1 are inserted within the cholesterol-rich lipid film of the infection. Chemical consumption of cholesterol from HIV-1 particles inactivates their infectivity. We watched that different HIV- 1 strains show a extend of sensitivities to such treatment. Contrasts in affectability to cholesterol consumption may not be clarified by variety in Env components known to connected with cholesterol, counting the cholesterol-recognition theme and cytoplasmic tail of gp41. Utilizing antibody- binding measures, estimations of infection infectivity, and investigations of lipid layer arrange, we found that consumption of cholesterol from HIV-1 particles diminishes the conformational soundness of Env. It upgrades presentation of in part enigmatic epitopes on the trimer and increments affectability to structure-perturbing medications such as antibodies and cold denaturation. Substitutions within the cholesterol-interacting theme of gp41 initiated comparative impacts as consumption of cholesterol [4]. Surface-acting operators, which are consolidated into the infection lipid film, caused comparable impacts as disturbance of the Env- cholesterol interaction. Besides, substitutions in gp120 that expanded basic soundness of Env (i.e. initiated a “closed” adaptation of the trimer) expanded infection resistance to cholesterol exhaustion and to the surface-acting specialists. Collectively, these comes about demonstrate a basic commitment of the viral film to the solidness of the Env trimer and to neutralization resistance against antibodies. Our discoveries propose that the power of ineffectively neutralizing antibodies, which are commonly inspired in immunized people, may be uniquely upgraded by modifying the lipid composition of the viral membrane [5].


  1. Richman DD, Wrin T , Little S J et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci. 2003;100:4144–49.
  2. Indexed at, Google Scholar, Cross Ref

  3. Moulard M , Phogat S K , Shu Y , Labrijn A F, et al. Broadly cross?reactive HIV?1?neutralizing human monoclonal Fab selected for binding to gp120?CD4?CCR5 complexes. Proc Natl Acad Sci. 2002;99:6913–18.
  4. Indexed at, Google Scholar, Cross Ref

  5. Mascola, J R, Lewis M G, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodefiency virus 89. 6PD by passive transfer of neutralizing antibodies. J Virol. 1999;73:4009–18.
  6. Indexed at, Google Scholar, Cross Ref

  7. Gurtle L G, Hauser P H, Eberle J, et al. A new subtype of human immunodeficiency virus type I (MVP? 5180) from Cameroon. J Virol. 1994;68:1581–85.
  8. Indexed at, Google Scholar, Cross Ref

  9. Denisova G, Stern B , Raviv D, et al. Humoral immune response to immunocomplexed HIV envelope glycoprotein 120. AIDS Res Hum Retroviruses. 1996;12:901–09.
  10. Indexed at, Google Scholar, Cross Ref

Get the App